Keytruda (pembrolizumab) has been cleared for patients with advanced endometrial cancer whose tumours have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) mutations ...

For information, the company have announced that the trial for pembrolizumab plus lenvatinib in endometrial cancer did not meet its primary endpoint and therefore they will no longer be pursuing a ...

Among patients with advanced or recurrent endometrial cancer (aEC), first-line treatment with Lenvima (lenvatinib) plus Keytruda (pembrolizumab) did not result in statistically significant ...

Endometrial cancer is the malignancy with the highest ... Last year MSD reported data from its pivotal NRG-GY018 study of Keytruda (pembrolizumab) plus chemo, which was filed with the FDA in ...

Approximately 90% of patients diagnosed with endometrial cancer present with complaints of irregular or postmenopausal vaginal bleeding. However, this symptom is not specific and can also occur ...

At the ASCO 2024, four clinically very important abstracts in endometrial cancer were presented. Long-term survival for ...

“If approved, KEYTRUDA would be the first immunotherapy indicated for the frontline treatment of advanced endometrial cancer regardless of mismatch repair status,” said Dr. Gursel ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable ... 4 June 2025 Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966] Technology ...